Status: Recruiting
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
To evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Participants needed: 380
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: CSPC Megalith Biopharmaceutical Co.,Ltd.Updated: Jul 1, 2026Locations: 1
Eligibility criteria
Aged 18-75 (inclusive) years old, male or females; [+7]
Histologically or cytologically confirmed combined small cell lung cancer,squamo... [+24]